Discovering New Therapeutic Uses for Existing Molecules
Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses) is a collaborative program designed to develop partnerships between pharmaceutical companies and the biomedical research community to advance therapeutics development. This innovative program matches researchers with a selection of pharmaceutical industry agents to test ideas for new therapeutic uses, with the ultimate goal of identifying promising new treatments for patients.
Therapeutic development is a costly, complex and time-consuming process. The average length of time from target discovery to approval of a new drug is about 14 years. The failure rate during this process exceeds 95 percent, and the cost per successful drug can be $2 billion or more. The high therapeutic development failure rate means there are many existing, partially developed therapeutic candidates that could be repurposed for use in a new disease indication. Bringing together the best agents from pharmaceutical companies with the best new ideas from academic researchers could produce new treatments much more quickly than starting from scratch.
Launched in May 2012, NCATS' New Therapeutic Uses program helps re-engineer the research pipeline using an innovative strategy to identify new uses for agents that have undergone significant research and development by industry, including safety testing in humans. By using agents that already have cleared several key steps in the development process, scientists nationwide have a strong starting point to contribute their unique expertise and accelerate the pace of therapeutics development.
There are no open NTU funding opportunities at this time. Information about future opportunities will appear on this page.
The most recent round of funding opportunities, which closed in January 2015, built upon the pilot phase of the program. In June 2013 in response to the initial set of funding announcements, NIH awarded $12.7 million to nine academic research groups for projects to explore new treatments for patients in eight disease areas, including two rare diseases.
The New Therapeutic Uses Industry-Provided Agents have undergone significant pre-clinical, safety and dosing testing and are ready for additional testing in humans. In 2014, NCATS collaborated with AstraZeneca, Janssen Research & Development, L.L.C., Pfizer Inc. and Sanofi to make 26 agents available, including several suitable for exploring pediatric indications.
In 2012, NCATS collaborated with Abbott, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, L.L.C., Pfizer, and Sanofi to make 58 agents available to researchers.
To facilitate and speed academia-industry collaborations, NIH developed template agreements designed to streamline the legal and administrative process for research collaboration by multiple organizations. These agreements help facilitate complex negotiations among all parties involved in the program, enabling the research to begin faster. In fact, one third of the project investigators in the New Therapeutic Uses pilot phase were testing compounds in humans for new uses within three months of receipt of funding, including potential treatments for schizophrenia and Alzheimer's disease.
Christine Colvis, 301-451-3903
Alzheimer's Disease News
On March 31, 2015, NCATS announced that scientists at Yale University have found that a compound originally developed as a cancer therapy potentially could be used to treat Alzheimer's disease. Now the team is testing the compound's effectiveness in humans.